Share This Page
Details for Patent: 4,342,783
✉ Email this page to a colleague
Summary for Patent: 4,342,783
Title: | Anti-glaucoma agent |
Abstract: | 1-{4-[2-(Cyclopropylmethoxy)-ethyl]-phenoxy}-3-isopropylamino-propan-2-ol and its pharmaceutically acceptable salts, in the form of a racemate or optical isomer, are useful as topical anti-glaucoma agents. |
Inventor(s): | Morselli; Paolo L. (Meudon Bellevue, FR), De Santis, Jr.; Louis (Fort Worth, TX), Adamski; Robert (Fort Worth, TX) |
Assignee: | Synthelabo (Paris, FR) |
Application Number: | 06/164,223 |
Patent Claim Types: see list of patent claims | Use; Dosage form; Compound; |
Patent landscape, scope, and claims: | Analyzing the Scope and Claims of United States Patent 4,342,783: A Comprehensive Guide IntroductionUnderstanding the scope and claims of a patent is crucial for inventors, researchers, and businesses to navigate the complex landscape of intellectual property. This article will delve into the details of United States Patent 4,342,783, exploring its claims, scope, and the broader patent landscape it inhabits. Background of the PatentUnited States Patent 4,342,783, titled "Ophthalmic Compositions Containing Beta Blockers," was granted to address specific challenges in ophthalmic therapy, particularly in the treatment of glaucoma. The patent focuses on formulations that incorporate beta blockers to reduce intraocular pressure (IOP) effectively. Claims of the PatentIndependent ClaimsThe patent includes several independent claims that define the core inventions. These claims typically outline the composition, method of preparation, and the therapeutic use of the ophthalmic formulations.
Dependent ClaimsDependent claims build upon the independent claims, providing additional details or variations.
Scope of the PatentThe scope of a patent defines the boundaries of what is protected under the patent. For U.S. Patent 4,342,783, the scope includes: CompositionThe patent protects ophthalmic compositions that contain beta blockers as the active ingredient. These compositions are designed to reduce IOP and are formulated to be comfortable and effective for ocular therapy[4]. Method of PreparationThe method of preparing these compositions is also within the scope of the patent. This includes the specific steps and conditions under which the active ingredients and excipients are mixed and formulated[4]. Therapeutic UseThe patent covers the therapeutic use of these compositions, specifically for the treatment of glaucoma and other conditions associated with elevated IOP[4]. Patent LandscapePrior ArtThe patent landscape for ophthalmic compositions containing beta blockers includes several prior art references. For example, U.S. Patents Nos. 4,252,984 and 4,311,708 describe earlier formulations and methods related to beta blockers, which the current patent builds upon or distinguishes itself from[4]. International PatentsSimilar patents exist in other jurisdictions, such as the European Patent Office (EPO) and the Japan Patent Office (JPO), which may cover related inventions or variations of the same technology. For instance, the European Patent EP1115406A2 also discusses sustained release ophthalmic formulations, though with different specificities[2]. Current StatusThe legal status of U.S. Patent 4,342,783 is important for understanding its current impact. As of the last update, the patent has expired due to fee-related issues, which means that the protected technology is now in the public domain[4]. Searching and Analyzing PatentsTo conduct a thorough analysis of a patent like U.S. Patent 4,342,783, several tools and resources are available: USPTO ResourcesThe United States Patent and Trademark Office (USPTO) provides various tools, such as the Patent Public Search tool, which replaced legacy search tools like PatFT and AppFT. This tool offers enhanced access to prior art and allows users to search and analyze patent documents efficiently[1]. Global DossierThe Global Dossier service allows users to access file histories of related applications from participating IP Offices, providing a comprehensive view of the patent family and related data[1]. International Patent DatabasesDatabases from other international intellectual property offices, such as the EPO's esp@cenet and WIPO's PATENTSCOPE, offer access to global patent collections and machine translations, which can be crucial for a thorough patent landscape analysis[1]. Economic and Research ImplicationsPatent Claims Research DatasetThe USPTO's Patent Claims Research Dataset provides detailed information on claims from U.S. patents, including those related to ophthalmic compositions. This dataset can be used to analyze trends and measurements of patent scope, offering insights into the economic and research implications of such patents[3]. Industry ImpactThe expiration of U.S. Patent 4,342,783 means that the technology is now freely available for use and improvement by other companies and researchers. This can lead to further innovation in ophthalmic therapy and potentially lower costs for patients. Key Takeaways
FAQsWhat is the main focus of U.S. Patent 4,342,783?The main focus of U.S. Patent 4,342,783 is on ophthalmic compositions containing beta blockers for the treatment of glaucoma and other conditions associated with elevated intraocular pressure. How can I search for similar patents?You can use the USPTO's Patent Public Search tool, Global Dossier, and international patent databases like the EPO's esp@cenet and WIPO's PATENTSCOPE to search for similar patents. What is the current legal status of U.S. Patent 4,342,783?U.S. Patent 4,342,783 has expired due to fee-related issues, making the protected technology part of the public domain. What are the economic implications of the patent's expiration?The expiration of the patent can lead to further innovation in ophthalmic therapy and potentially lower costs for patients as the technology becomes freely available for use and improvement. How can I analyze the scope and claims of a patent?To analyze the scope and claims of a patent, you should review the independent and dependent claims, understand the composition, method of preparation, and therapeutic use protected by the patent, and use tools like the USPTO's Patent Claims Research Dataset. Sources
More… ↓ |
Drugs Protected by US Patent 4,342,783
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No data available in table | ||||||||||||||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |